week 2 on semaglutide 2·4 mg once a in adults with overweight or obesity, and type diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial SEMAGLUTIDE JOURNEY *week 2* //

A patient losing 20-25% of body weight (typically 20-30 kg) would expect 10-20 mmHg systolic improvement based on this rule of thumb

Chronic activation of astrocytes and microglia leads to the release of cytokines involved in inflammation, chemokines, and other inflammatory mediators

The medication's appetite-suppressing effects fade, and you may notice increased hunger and food cravings returning to pre-treatment levels or potentially higher

Many patients feel a boost in energy and mental clarity within 2472 hours of their injection

The Incretin Axis: Endocrinological Background GLP-1 and GIP are incretin hormones peptides secreted from intestinal endocrine cells in response to nutrient ingestion that amplify pancreatic insulin secretion in a glucose-dependent manner